Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160339 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
A Phase 1 study, sponsored by Emergent BioSolutions.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03160339 is a Phase 1 study that was terminated before completion, run by Emergent BioSolutions. The registered enrollment target is 25 participants.
The verdict
NCT03160339, a Phase 1 study, was terminated before completion, sponsored by Emergent BioSolutions.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine \[A549 Cells\], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immunogenicity of PXVX0047.
Interventions
- BIOLOGICAL PXVX0047 Vaccine
- BIOLOGICAL Teva Ad4/Ad7 Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03160339
The ClinicalTrials.gov registry entry for NCT03160339 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PXVX0047 Vaccine is the first listed.
NCT03160339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03160339 about?
NCT03160339 is a clinical study titled "A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047". PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine \[A549 Cells\], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immun...
What is the current status of trial NCT03160339?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-05-01. Estimated completion is 2017-11-27.
What interventions are being tested in trial NCT03160339?
The interventions under investigation include: PXVX0047 Vaccine (BIOLOGICAL), Teva Ad4/Ad7 Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03160339?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.